A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma

• Research surrounding treatment of leiomyosarcoma (LMS) treatment remains sparse. • Pembrolizumab/lenvatinib has been reported as a therapy for endometrial cancer, though not yet as therapy for LMS. • This report demonstrates disease regression after use of pembrolizumab and lenvatinib in a patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Naaman, Lee, Sarah S., Salame, Ghadir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932649/
https://www.ncbi.nlm.nih.gov/pubmed/36818196
http://dx.doi.org/10.1016/j.gore.2023.101145
_version_ 1784889500132966400
author Mehta, Naaman
Lee, Sarah S.
Salame, Ghadir
author_facet Mehta, Naaman
Lee, Sarah S.
Salame, Ghadir
author_sort Mehta, Naaman
collection PubMed
description • Research surrounding treatment of leiomyosarcoma (LMS) treatment remains sparse. • Pembrolizumab/lenvatinib has been reported as a therapy for endometrial cancer, though not yet as therapy for LMS. • This report demonstrates disease regression after use of pembrolizumab and lenvatinib in a patient with recurrent LMS.
format Online
Article
Text
id pubmed-9932649
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99326492023-02-17 A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma Mehta, Naaman Lee, Sarah S. Salame, Ghadir Gynecol Oncol Rep Case Report • Research surrounding treatment of leiomyosarcoma (LMS) treatment remains sparse. • Pembrolizumab/lenvatinib has been reported as a therapy for endometrial cancer, though not yet as therapy for LMS. • This report demonstrates disease regression after use of pembrolizumab and lenvatinib in a patient with recurrent LMS. Elsevier 2023-01-27 /pmc/articles/PMC9932649/ /pubmed/36818196 http://dx.doi.org/10.1016/j.gore.2023.101145 Text en © 2023 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Mehta, Naaman
Lee, Sarah S.
Salame, Ghadir
A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
title A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
title_full A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
title_fullStr A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
title_full_unstemmed A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
title_short A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
title_sort case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932649/
https://www.ncbi.nlm.nih.gov/pubmed/36818196
http://dx.doi.org/10.1016/j.gore.2023.101145
work_keys_str_mv AT mehtanaaman acaseofpembrolizumabandlenvatinibasanalterntivetherapyforleiomyosarcoma
AT leesarahs acaseofpembrolizumabandlenvatinibasanalterntivetherapyforleiomyosarcoma
AT salameghadir acaseofpembrolizumabandlenvatinibasanalterntivetherapyforleiomyosarcoma
AT mehtanaaman caseofpembrolizumabandlenvatinibasanalterntivetherapyforleiomyosarcoma
AT leesarahs caseofpembrolizumabandlenvatinibasanalterntivetherapyforleiomyosarcoma
AT salameghadir caseofpembrolizumabandlenvatinibasanalterntivetherapyforleiomyosarcoma

Ejemplares similares